Benjamin L. Oakes
CIK: 0002127814
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Scribe Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
264.8K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectPerformance-based Stock Option (Right to Buy)
429.6K shares- - Mar 13, 2026SCTX
Scribe Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
13K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 264,784 | - | - | Direct |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Performance-based Stock Option (Right to Buy) | 429,599 | - | - | Direct |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 12,969 | - | - | Direct |
1-3 of 3 transactions
About Oakes Benjamin L.
Oakes Benjamin L. (SEC CIK 0002127814) files insider reports with the SEC as President, CEO of Scribe Therapeutics, Inc. (SCTX).
Signal8 holds 2 ownership filings by Oakes Benjamin L. (1 Form 3, 1 Form 4), filed between Jul 23, 2026 and Jul 27, 2026. Those filings report 3 transactions, from Mar 13, 2026 to Jul 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Oakes Benjamin L.'s filings is in ALAMEDA, CA.
Recent filings by Oakes Benjamin L.
Other insiders filing for Scribe Therapeutics, Inc. (SCTX)
- AH Bio Fund II, L.P., 10% Owner
- GORDON CARL L, Director
- ORBIMED ADVISORS LLC, Director
- Doudna Jennifer A, 10% Owner
- Aghazadeh Behzad, Director
- Staahl Brett, 10% Owner